Santen Pharmaceuticals

With a growing armamentarium for glaucoma, balancing safety and efficacy is the modern-day challenge

Highlights from the “Decoding Glaucoma: A place for 24-hour IOP control” educational symposium organized by Santen and held at the 13th EGS Congress, Florence, Italy, on May 19, 2018. The symposium was moderated by Carlo Traverso (University of Genova, Italy), and featured presentations and comments from Luciano Quaranta (University of Brescia, Italy), Antonio Figueiredo (University of Lisbon, Portugal), and Anastasios Konstas (Aristotle University of Thessaloniki, Greece).

Preservatives in topical glaucoma therapy: they risk ocular surface disease and future filtration surgery failure, and do nothing to improve efficacy. Is it time to leave them behind?

Dry eye disease is hugely prevalent, hard to diagnose, and in the case of severe disease, can be extremely difficult to treat. What can be done to improve matters?

Preserved glaucoma product use increases the probability that future glaucoma surgery will fail. Let’s examine the literature…

Taking the time to talk with patients about the signs and symptoms of ocular surface disease and performing some quick assessments could ensure selection of the most appropriate therapy, and help improve patient outcomes

Why persist with preservatives? Those present in topical glaucoma therapies don’t improve the active compound’s efficacy – and cause ocular surface disease in many patients

The first and only EU-approved ciclosporin eyedrop has arrived – what does this mean for patients with severe keratitis in dry eye disease?

As many as six in every ten patients with glaucoma have ocular surface disease – and this can have a huge impact on their daily lives. We explore why, and what can be done.

Managing dry eye disease becomes disproportionately more difficult as the severity of the disease increases: artificial tears and lubricants are not enough to help patients with severe dry eye disease.